Peter Boyd Net Worth

The estimated Net Worth of Peter E. Boyd is at least $295 Thousand dollars as of 14 June 2022. Mr. Boyd owns over 5,000 units of Aquestive Therapeutics Inc stock worth over $294,683 and over the last 6 years he sold AQST stock worth over $0. In addition, he makes $0 as Senior Vice President - Business Process and Information Technology at Aquestive Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Boyd AQST stock SEC Form 4 insiders trading

Peter has made over 5 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of AQST stock worth $4,050 on 14 June 2022.

The largest trade he's ever made was buying 5,000 units of Aquestive Therapeutics Inc stock on 14 June 2022 worth over $4,050. On average, Peter trades about 673 units every 87 days since 2018. As of 14 June 2022 he still owns at least 59,532 units of Aquestive Therapeutics Inc stock.

You can see the complete history of Mr. Boyd stock trades at the bottom of the page.

Peter Boyd biography

Peter E. Boyd serves as Senior Vice President - Business Process and Information Technology of the Company. Mr. Boyd joined our Company in August 2013 and has led our Business Process and Information Technology functions since May 2019. Prior to his current position, Mr. Boyd led our Operations and Value Delivery functions from April 2014 to May 2019. Prior to joining us, Mr. Boyd served as Senior Director of Operations for the Americas and APJ Regions at Hewlett-Packard Company. Throughout his 15-year career at the Hewlett-Packard Company, Mr. Boyd held a variety of positions in business process improvement and in operations. Mr. Boyd received a B.A. in History from Wittenberg University and an M.B.A in Finance from Seton Hall University. Mr. Boyd also received an M.S. in Management and Urban Policy Analysis from the New School University.

How old is Peter Boyd?

Peter Boyd is 54, he's been the Senior Vice President - Business Process and Information Technology of Aquestive Therapeutics Inc since 2019. There are 19 older and 2 younger executives at Aquestive Therapeutics Inc. The oldest executive at Aquestive Therapeutics Inc is Gregory Brown, 66, who is the Independent Director.

What's Peter Boyd's mailing address?

Peter's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.

Insiders trading at Aquestive Therapeutics Inc

Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker, and Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.

What does Aquestive Therapeutics Inc do?

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Complete history of Mr. Boyd stock trades at Aquestive Therapeutics Inc

Aquestive Therapeutics Inc executives and stock owners

Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include:

• A. Mark Schobel,
  Chief Innovation and Technology Officer
• Keith Kendall,
  President, Chief Executive Officer, Director
• Daniel Barber,
  Chief Operating Officer, Senior Vice President
• John Maxwell,
  Senior Vice President, Chief Financial Officer
• Keith J. Kendall,
  CEO, Pres & Director
• Daniel Barber,
  Sr. VP & COO
• Santo Costa,
  Independent Chairman of the Board
• James Scibetta,
  Independent Director
• Douglas Bratton,
  Independent Director
• Nancy Lurker,
  Independent Director
• Gregory Brown,
  Independent Director
• John Cochran,
  Vice Chairman of the Board
• Gary Slatko,
  Senior Vice President, Chief Medical Officer
• Kenneth Marshall,
  Senior Vice President - Chief Commercial Officer
• Peter Boyd,
  Senior Vice President - Business Process and Information Technology
• Theresa Wood,
  Senior Vice President - Human Resources and Organizational Development
• Lori Braender,
  Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
• Dr. Gary H. Slatko M.D., MBA,
  Sr. VP & Chief Medical Officer
• Kenneth W. Marshall,
  Sr. VP & Chief Commercial Officer
• Peter E. Boyd,
  Sr. VP of Bus. Process & Information Technology
• Dr. Eric Dadey Ph.D.,
  Sr. Vice-Pres of R&D
• Theresa Wood,
  Sr. VP of HR & Organizational Devel.
• Lori J. Braender Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Alexander Mark Schobel,
  Chief Innovation & Technology Officer
• A. Ernest Toth Jr.,
  Sr. VP & CFO
• Timothy E Morris,
  
• Ken W. Marshall,
  SVP, Chief Commercial Officer
• Marco Taglietti,
  
• Julie Krop,
  
• Douglas K Monoline Partners...,
  
• Cassie Jung,
  SVP, Operations
• Douglas K Mono Line Partner...,
  
• Kenneth Truitt,
  Chief Medical Officer
• A Ernest Jr Toth,
  SVP, Chief Financial Officer
• Carl N Kraus,
  Chief Medical Officer
• Stephen Wargacki,
  Chief Science Officer
• Abigail L. Jenkins,
  
• Sherry Korczynski,
  SVP Sales and Marketing